NCT06183229View on ClinicalTrials.gov

Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza

PHASE3CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

March 1, 2024

Study Completion Date

June 10, 2024

Conditions
InfluenzaAcute Respiratory Infection
Interventions
DRUG

Cycloferon

Cycloferon, enteric-coated tablets, 150 mg, 4 tablets (600 mg) per day on days 1, 2, 4, 6 and 8.

DRUG

Placebo

Placebo tablets, 4 tablets per day on days 1, 2, 4, 6 and 8

Trial Locations (2)

196143

Research Center for Eco-safety, Ltd., Saint Petersburg

Unknown

City Outpatient Clinic #117, Saint Petersburg

All Listed Sponsors
lead

POLYSAN Scientific & Technological Pharmaceutical Company

INDUSTRY

NCT06183229 - Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza | Biotech Hunter | Biotech Hunter